Akouos, Inc. (AKUS)

$ 9.5
-0.26 (-2.66%)
-
Symbol AKUS
Price $ 9.5
Beta 0.000
Volume Avg. 0.08M
Market Cap 0.33B
Shares () -
52 Week Range 9.39-23.49
1y Target Est -
DCF Unlevered AKUS DCF ->
DCF Levered AKUS LDCF ->
ROE -21.39% Sell
ROA -20.36% Sell
Operating Margin -
Debt / Equity 14.48% Neutral
P/E -
P/B 1.18 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AKUS news


Dr. Emmanuel Simons M.B.A., Ph.D.
Healthcare
Biotechnology
Nasdaq Global Select

Akouos, Inc., a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts.